Annexon Biosciences (ANNX)
NASDAQ:ANNX

Annexon Biosciences Stock Analysis & Ratings

ANNX Stock Chart & Stats

Day’s Range$2.96 - $3.29
52-Week Range$2.06 - $24.85
Previous Close$3.04
Volume345.85K
Average Volume (3M)510.62K
Market Cap$126.10M
P/E Ratio-0.9
Beta0.82
Next EarningsAug 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-3.63


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ANNX FAQ

What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $2.06 and its highest was $24.85 in the past 12 months.
    What is Annexon Biosciences’s market cap?
    Annexon Biosciences’s market cap is $126.10M.
      What is Annexon Biosciences’s price target?
      The average price target for Annexon Biosciences is $26.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $30.00 ,the lowest forecast is $24.00. The average price target represents 695.11% Increase from the current price of $3.27.
        What do analysts say about Annexon Biosciences?
        Annexon Biosciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Annexon Biosciences’s upcoming earnings report date?
          Annexon Biosciences’s upcoming earnings report date is Aug 15, 2022 which is in 79 days.
            How were Annexon Biosciences’s earnings last quarter?
            Annexon Biosciences released its earnings results on May 09, 2022. The company reported -$0.92 earnings per share for the quarter, beating the consensus estimate of -$0.99 by $0.07.
              Is Annexon Biosciences overvalued?
              According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
                Does Annexon Biosciences pay dividends?
                Annexon Biosciences does not currently pay dividends.
                What is Annexon Biosciences’s EPS estimate?
                Annexon Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Annexon Biosciences have?
                Annexon Biosciences has 38,560,000 shares outstanding.
                  What happened to Annexon Biosciences’s price movement after its last earnings report?
                  Annexon Biosciences reported an EPS of -$0.92 in its last earnings report, beating expectations of -$0.99. Following the earnings report the stock price went up 23.077%.
                    Which hedge fund is a major shareholder of Annexon Biosciences?
                    Among the largest hedge funds holding Annexon Biosciences’s share is Deerfield Management Company, LP. It holds Annexon Biosciences’s shares valued at 2M.

                      ---

                      Annexon Biosciences Stock Analysis

                      The Annexon Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Annexon Biosciences

                      Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.

                      ---
                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis